Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia by Parkkinen, L, Kauppinen, T, Pirttilä, T, Autere, J, Alafuzoff, I, Parkkinen, L

Gut feeling about alpha-synuclein in gastro-intestinal biopsies: biomarker in the making? by Ruffmann, C, Parkkinen, L

Gut feelings about α-synuclein in gastrointestinal biopsies: biomarker in the making? by Ruffmann, C, Parkkinen, L

Is levodopa toxic? Insights from pathological studies by Parkkinen, L, Lees, A

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance by Parkkinen, L, Pirttilä, T, Alafuzoff, I

Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms by Parkkinen, L, Hartikainen, P, Alafuzoff, I

Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease by Parkkinen, L, Soininen, H, Alafuzoff, I

Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects by Aho, L, Parkkinen, L, Pirttilä, T, Alafuzoff, I

Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject by Parkkinen, L, Pirttilä, T, Tervahauta, M, Alafuzoff, I

Relationship of Apolipoprotein E to Parkinson's disease-related alpha-synuclein pathology by Parkkinen, L, Joachim, C, Esiri, M, Ansorge, O

Association of MAPT (tau) haplotype with the pathology of Parkinson's disease by Parkkinen, L, Joachim, C, Esiri, M, Ansorge, O

Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture by Chia, R, Sabir, MS, Bandres-Ciga, S, Parkkinen, L, Ansorge, O

Can olfactory bulb biopsy be justified for the diagnosis of Parkinson’s disease? Comments on “olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body di... by Parkkinen, L, Silveira-Moriyama, L, Holton, J, Lees, A, Revesz, T

Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders by Altay, MF, Liu, AKL, Holton, JL, Parkkinen, L, Lashuel, HA

Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain by Tapiola, T, Alafuzoff, I, Herukka, S, Parkkinen, L, Hartikainen, P, Soininen, H, Pirttilä, T

LRP10 in α-synucleinopathies by Guerreiro, R, Orme, T, Neto, JL, Bras, J, Parkkinen, L, Ansorge, O

Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinson's disease by O'Sullivan, S, Collins, C, Petrie, A, Holton, J, Revesz, T, Lees, A, Parkkinen, L

Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease by Parkkinen, L, Neumann, J, O'Sullivan, S, Holton, J, Revesz, T, Hardy, J, Lees, A

Human-specific transcriptome of ventral and dorsal midbrain dopamine neurons by Monzón-Sandoval, J, Poggiolini, I, Ilmer, T, Wade-Martins, R, Webber, C, Parkkinen, L

The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia by Compta, Y, Parkkinen, L, Kempster, P, Selikhova, M, Lashley, T, Holton, J, Lees, A, Revesz, T